RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTIONS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Nasal spray vaccine aims to shield children from RSV
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tests an experimental RSV vaccine called CodaVax-RSV, given as nose drops, in healthy children aged 6 months to 5 years. The study evaluates the vaccine's safety and the immune response it triggers. Some children receive the vaccine at different doses, whil…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: Codagenix, Inc • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 17, 2026 00:00 UTC
-
New oral pill aims to fight RSV in adults
Disease control TerminatedThis study tests an oral drug called AK0529 (Ziresovir) in adults aged 18 to 75 with respiratory syncytial virus (RSV) infection. Participants receive either the drug or a placebo, and researchers measure how well symptoms improve and track any side effects. The goal is to see if…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE2 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New RSV drug tested in kids – but trial halted early
Disease control TerminatedThis study tested the safety and dosing of sisunatovir, an experimental antiviral drug, in infants and children up to 5 years old with RSV lower respiratory tract infection. Ten participants received either the drug or a placebo. The goal was to find the right dose for future stu…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC